Latest Insider Transactions at Cytokinetics Inc (CYTK)
This section provides a real-time view of insider transactions for Cytokinetics Inc (CYTK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CYTOKINETICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CYTOKINETICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 12
2021
|
Sandford D Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+45.79%
|
-
|
|
May 12
2021
|
B Lynne Parshall Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
May 12
2021
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+45.79%
|
-
|
|
May 12
2021
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+47.81%
|
-
|
|
May 07
2021
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.38%
|
$115,000
$23.21 P/Share
|
|
May 07
2021
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.36%
|
$30,000
$6.3 P/Share
|
|
Apr 30
2021
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.38%
|
$125,000
$25.87 P/Share
|
|
Apr 30
2021
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.36%
|
$30,000
$6.3 P/Share
|
|
Apr 27
2021
|
Sandford D Smith Director |
SELL
Open market or private sale
|
Direct |
9,739
-84.1%
|
$262,953
$27.75 P/Share
|
|
Apr 27
2021
|
Sandford D Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,739
+45.68%
|
$97,390
$10.62 P/Share
|
|
Apr 26
2021
|
Sandford D Smith Director |
SELL
Open market or private sale
|
Direct |
5,000
-84.46%
|
$135,000
$27.0 P/Share
|
|
Apr 26
2021
|
Sandford D Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+45.79%
|
$45,000
$9.45 P/Share
|
|
Apr 23
2021
|
Sandford D Smith Director |
SELL
Open market or private sale
|
Direct |
5,000
-84.46%
|
$130,000
$26.5 P/Share
|
|
Apr 23
2021
|
Sandford D Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+45.79%
|
$45,000
$9.45 P/Share
|
|
Apr 15
2021
|
Sandford D Smith Director |
SELL
Open market or private sale
|
Direct |
10,714
-85.3%
|
$267,850
$25.25 P/Share
|
|
Apr 15
2021
|
Sandford D Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,714
+46.03%
|
$96,426
$9.1 P/Share
|
|
Apr 12
2021
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.38%
|
$115,000
$23.56 P/Share
|
|
Apr 12
2021
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.36%
|
$30,000
$6.3 P/Share
|
|
Apr 09
2021
|
Sandford D Smith Director |
SELL
Open market or private sale
|
Direct |
27,582
-83.03%
|
$634,386
$23.95 P/Share
|
|
Apr 09
2021
|
Sandford D Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
27,582
+45.35%
|
$193,074
$7.88 P/Share
|
|
Apr 08
2021
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.22%
|
$46,000
$23.39 P/Share
|
|
Apr 01
2021
|
Robert Califf Director |
BUY
Grant, award, or other acquisition
|
Direct |
204
+30.77%
|
$4,896
$24.44 P/Share
|
|
Apr 01
2021
|
L Patrick Gage Director |
BUY
Grant, award, or other acquisition
|
Direct |
767
+3.29%
|
$18,408
$24.44 P/Share
|
|
Apr 01
2021
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
409
+30.78%
|
$9,816
$24.44 P/Share
|
|
Apr 01
2021
|
Sandford D Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
409
+30.78%
|
$9,816
$24.44 P/Share
|
|
Apr 01
2021
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
409
+30.78%
|
$9,816
$24.44 P/Share
|
|
Apr 01
2021
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
204
+30.77%
|
$4,896
$24.44 P/Share
|
|
Apr 01
2021
|
John T Henderson Director |
SELL
Open market or private sale
|
Direct |
3,333
-13.04%
|
$76,659
$23.54 P/Share
|
|
Apr 01
2021
|
John T Henderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,333
+11.53%
|
$26,664
$8.64 P/Share
|
|
Mar 22
2021
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-0.69%
|
$125,000
$25.19 P/Share
|
|
Mar 22
2021
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+0.69%
|
$30,000
$6.15 P/Share
|
|
Mar 19
2021
|
L Patrick Gage Director |
SELL
Open market or private sale
|
Direct |
10,000
-31.48%
|
$240,000
$24.45 P/Share
|
|
Mar 19
2021
|
L Patrick Gage Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+23.95%
|
$50,000
$5.88 P/Share
|
|
Mar 12
2021
|
L Patrick Gage Director |
SELL
Open market or private sale
|
Direct |
10,339
-18.82%
|
$217,119
$21.22 P/Share
|
|
Mar 12
2021
|
L Patrick Gage Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,339
+15.65%
|
$72,373
$7.26 P/Share
|
|
Mar 11
2021
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.2%
|
$38,000
$19.9 P/Share
|
|
Mar 08
2021
|
Robert I Blum President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
23,799
-6.25%
|
$452,181
$19.19 P/Share
|
|
Mar 08
2021
|
David Cragg Chief HR & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,150
-2.52%
|
$78,850
$19.19 P/Share
|
|
Mar 08
2021
|
Ching Jaw SVP Finance & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,150
-4.48%
|
$78,850
$19.19 P/Share
|
|
Mar 08
2021
|
Fady Ibraham Malik EVP Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
7,634
-4.39%
|
$145,046
$19.19 P/Share
|
|
Mar 08
2021
|
Mark A Schlossberg SVP - Legal & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
4,150
-7.55%
|
$78,850
$19.19 P/Share
|
|
Mar 08
2021
|
Robert Wong VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,359
-5.38%
|
$25,821
$19.19 P/Share
|
|
Mar 08
2021
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.3%
|
$95,000
$19.49 P/Share
|
|
Mar 08
2021
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.28%
|
$30,000
$6.0 P/Share
|
|
Mar 02
2021
|
Robert I Blum President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+17.37%
|
-
|
|
Mar 02
2021
|
David Cragg Chief HR & Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+13.17%
|
-
|
|
Mar 02
2021
|
Ching Jaw SVP Finance & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+21.25%
|
-
|
|
Mar 02
2021
|
Fady Ibraham Malik EVP Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+16.75%
|
-
|
|
Mar 02
2021
|
Mark A Schlossberg SVP - Legal & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+31.25%
|
-
|
|
Mar 02
2021
|
Robert Wong VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+28.38%
|
-
|